共 24 条
- [1] FT576: Multi-Specific Off-the-Shelf CAR-NK Cell Therapy Engineered for Enhanced Persistence, Avoidance of Self-Fratricide and Optimized Mab Combination Therapy to Prevent Antigenic Escape and Elicit a Deep and Durable Response in Multiple MyelomaBLOOD, 2020, 136Goodridge, Jode P.Bjordahl, RyanMahmood, SajidReiser, JohnGaidarova, SvetlanaBlum, RobertCichocki, FrankChu, Hui-yiBonello, GregLee, TomGroff, BrianMeza, MiguelChu, Yu-WayeWalcheck, BruceMalmberg, Karl-JohanMiller, Jeffrey S.Rehm, ArminHopken, UtaValamehr, Bahram
- [2] Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapyJournal of Hematology & Oncology, 14Ying GongRoel G. J. Klein WolterinkJianxiang WangGerard M. J. BosWilfred T. V. Germeraad
- [3] Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapyJOURNAL OF HEMATOLOGY & ONCOLOGY, 2021, 14 (01)Gong, YingKlein Wolterink, Roel G. J.Wang, JianxiangBos, Gerard M. J.Germeraad, Wilfred T. V.
- [4] Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape-Driven Relapse in Multiple MyelomaBLOOD CANCER DISCOVERY, 2020, 1 (02): : 146 - 154de Larrea, Carlos FernandezStaehr, MetteLopez, Andrea, VNg, Khong Y.Chen, YunxinGodfrey, William D.Purdon, Terence J.Ponomarev, VladimirWendel, Hans-GuidoBrentjens, Renier J.Smith, Eric L.
- [5] Allogeneic CAR-NK Cell Therapy Targeting Both BCMA and GPRC5D for the Treatment of Multiple MyelomaBLOOD, 2022, 140 : 7378 - 7378Cao, ZhuoxiaoYang, CuiqingWang, YifangWang, ChaoWang, QingyangYe, GangLiu, TingtingWang, QinWang, HuanyuGong, YanxueWang, BiyeJiang, Fuwei
- [6] BCMA AND CD229 DUAL-TARGETED CAR T CELL EFFECTIVELY CONTROLS MULTIPLE MYELOMA WITH LOSS OF BCMA EXPRESSIONBONE MARROW TRANSPLANTATION, 2023, 58 (SUPP1) : 45 - 46Gerardo Rodriguez-Lobato, LuisCardus, OriolBattram, Joan Mane Anthony M.Perez-Amill, LorenaCalderon, HugoMartin-Antonio, BeatrizOliver-Caldes, AinaLozano, EsterMoreno, David F.Ortiz-Maldonado, ValentinQueralt Salas, Mariade Daniel i Bisbe, AnnaTovar, NataliaJimenez, RaquelTeresa Cibeira, M.Rosinol, LauraBlade, JoanJuan, ManelUrbano-Ispizua, AlvaroEngel, PabloFernandez de larrea, Carlos
- [7] Preclinical development of first-of-kind dual-targeted off-the-shelf CAR-NK cell product with engineered persistence for an effective treatment of B cell malignanciesCANCER RESEARCH, 2019, 79 (13)Goodridge, JodeMahmood, SajidZhu, HuangGaidarova, SvetlanaBlum, RobertBjordahl, RyanCichocki, FrankChu, Hui-YiBonello, GregLee, TomGroff, BrianMalmberg, Karl-JohanWalcheck, BruceMiller, JeffreyKaufman, DanValamehr, Bahram
- [8] Optimal Dual-Targeted CAR Construct Simultaneously Targeting Bcma and GPRC5D Prevents Bcma-Escape Driven Relapse in Multiple MyelomaBLOOD, 2019, 134de Larrea, Carlos FernandezStaehr, MetteLopez, AndreaChen, YunxinPurdon, Terence J.Ng, Khong Y.Wendel, HansBrentjens, Renier J.Smith, Eric L.
- [9] Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape-Driven Relapse in Multiple Myeloma (vol 1, pg 146, 2020)BLOOD CANCER DISCOVERY, 2024, 5 (02): : 132 - 132de Larrea, C. FernandezStaehr, M.Lopez, A., VNg, K. Y.Chen, Y.Godfrey, W. D.
- [10] Case report: Dual-targeted BCMA and CS1 CAR-T-cell immunotherapy in recurrent and refractory extramedullary multiple myelomaFRONTIERS IN IMMUNOLOGY, 2024, 15Shi, XiangjunWu, YueYao, XingchenDu, BoranDu, Xinru